AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Connacher, A. A.
Right arrow Articles by Jung, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Connacher, A. A.
Right arrow Articles by Jung, R. T.
Agricola
Right arrow Articles by Connacher, A. A.
Right arrow Articles by Jung, R. T.

American Journal of Clinical Nutrition, Vol 55, 258S-261S, Copyright © 1992 by The American Society for Clinical Nutrition, Inc

REVIEW ARTICLES

Clinical studies with the beta-adrenoceptor agonist BRL 26830A

AA Connacher, WM Bennet and RT Jung
Department of Medicine, Ninewells Hospital and Medical School, Dundee, Scotland, UK.

BRL 26830A is a beta-adrenoceptor agonist drug that shows a high degree of selectivity for thermogenesis and has potential as an antiobesity agent. We undertook a double-blind trial in 40 obese subjects who received either BRL 26830A or placebo for 18 wk. All were prescribed a 3.35 MJ (800 kcal) diet. Weight loss was 15.4 +/- 6.6 (SD) kg on BRL 26830A compared with 10.0 +/- 5.9 kg on placebo (P less than 0.02). The relative weight losses were 0.93% and 0.61%/wk, respectively. Urinary nitrogen excretion was similar in both groups and skinfold measurements indicated a 4-kg difference in fat lost, suggesting that weight loss was mainly from adipose tissue. Psychological assessments showed that BRL 26830A had no adverse effect on mood and no effect on hunger or satiety. Tremor was experienced by 12 of 16 treated subjects who completed the study. It was generally rated as mild, occurred 1 h after dosing, and tended to diminish with time on treatment. Subsequent analysis of the tremor suggested that it is an exaggeration of physiological tremor mediated through skeletal muscle beta 2 adrenoceptors.


This article has been cited by other articles:


Home page
 NEJMHome page
J. Walston, K. Silver, C. Bogardus, W. C. Knowler, F. S. Celi, S. Austin, B. Manning, A. D. Strosberg, M. P. Stern, N. Raben, et al.
Time of Onset of Non-Insulin-Dependent Diabetes Mellitus and Genetic Variation in the {beta}3-Adrenergic-Receptor Gene
N. Engl. J. Med., August 10, 1995; 333(6): 343 - 347.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The American Society for Nutrition